Memphasys Limited (FRA:IG7)

Germany · Delayed Price · Currency is EUR

0.0025

0.00 (0.00%)

Last updated: Jun 26, 2026, 8:11 AM CET

-28.57% (1Y)

Market Cap	13.08M +81.4%
Revenue (ttm)	121.56K +52.1%
Net Income	-2.51M
EPS	-0.00
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0025
Previous Close	0.0025
Day's Range	0.0025 - 0.0025
52-Week Range	0.0010 - 0.0050
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Memphasys

Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company offers Felix system, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, a rapid in vitro antioxidant assessment; and AI-Port, an ambient temperature semen transport device for artificial insemination in animals. In addition, the company develops ambient temperature storage p... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2006

Employees 24

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol IG7

Financial Performance

In fiscal year 2025, Memphasys's revenue was 526,921, an increase of 237.77% compared to the previous year's 156,000. Losses were -5.04 million, -6.19% less than in 2024.

Financial numbers in AUD Financial Statements